To gain further insight into adjuvant chemotherapy use and its impact on efficacy outcomes in resected NSCLC, a recent study that analyzed data from the ADAURA trial indicated that the adjuvant osimertinib was an effective treatment for patients with stage IB-IIIA EGFR-mutant NSCLC after resection, with or without prior adjuvant chemotherapy [11, 27]. Here, EGFR is linked to non-small cell lung carcinoma.